Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ilypsa has completed a phase I clinical trial for ILY101, an investigational drug that is being developed for the treatment of hyperphosphatemia, a serious complication in patients with chronic kidney disease on dialysis.
Subscribe to our email newsletter
The phase I study examined the safety and tolerability of single and multiple doses of orally-administered ILY101 in twenty-four healthy volunteers. With the successful completion of phase I, the company expects to initiate a phase II study in chronic kidney disease (CKD) patients on dialysis.
ILY101, a novel phosphate binding agent, works by reducing the systemic absorption of dietary phosphate. The drug is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs.
“Hyperphosphatemia is a serious disease characterized by abnormally elevated serum phosphate levels that can result in significant morbidity and mortality in end-stage renal disease patients,” noted Dr Detlef Albrecht, Ilypsa’s chief medical officer. “We are very encouraged by the outcome of our phase I study, and believe that ILY101 has the potential to offer an improved treatment option to patients who require chronic phosphate binder therapy.”